is exendin-4 in tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor Dual GLP-1 and GIP Agonist

Clinical data shows that weight regain typically begins 48 weeks after discontinuation if no lifestyle changes are maintained, with some patients regaining 50% of lost weight within one year without behavioral support

Any severe GI symptoms or allergic signs warrant prompt medical attention

To tackle this gap of knowledge, we aimed to interrogate the functional cell-autonomous rhythms in isolated primary L-cell culture, and in intestinal organoids

Lesjak, M

Association of estrogen receptor alpha (ERalpha) gene polymorphisms with endometrial thickness and lipid profile in women with breast cancer treated with aromatase inhibitors

When GLP-1 Medications Are No Longer Working for You By Trace Curry, MD, FASMBS Over the last several years, GLP-1 medications such as semaglutide and tirzepatide have changed the conversation around obesity treatment